NURIX THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
NURIX THERAPEUTICS, INC. (NRIX) reported Increase (Decrease) in Accounts Receivable of $0 for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-11-30 was $0.00.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-08-31 was $0.00, a 100.00% decline year-over-year.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-11-30 was -$2.00M.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-08-31 was $2.00M.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$6.00M, a 200.00% decline from fiscal 2021.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2021 was $6.00M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-05-31 | $0.00 10-Q · filed 2026-07-09 | |||
| 2025-05-31 | $19.00M 10-Q · filed 2026-07-09 | |||
| 2024-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $0.00 derived: sum of 2 quarters · filed 2025-01-28 | $0.00 10-K · filed 2025-01-28 | |
| 2024-08-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $0.00 10-Q · filed 2024-10-11 | ||
| 2024-05-31 | $0.00 10-Q · filed 2025-07-09 | |||
| 2023-11-30 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $0.00 derived: sum of 2 quarters · filed 2025-01-28 | $0.00 10-K · filed 2025-01-28 | |
| 2023-08-31 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $2.00M 10-Q · filed 2024-10-11 | ||
| 2023-05-31 | $0.00 10-Q · filed 2023-07-13 | |||
| 2022-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $0.00 derived: sum of 2 quarters · filed 2025-01-28 | -$6.00M 10-K · filed 2025-01-28 | |
| 2022-08-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | -$6.00M 10-Q · filed 2023-10-12 | ||
| 2022-05-31 | -$6.00M 10-Q · filed 2023-07-13 | |||
| 2021-11-30 | $6.00M 10-K · filed 2023-02-09 | |||
| 2021-05-31 | $2.54M 10-Q · filed 2022-07-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |